Author(s):
Sushil Yadaorao Raut, Manjunath B Joshi, Guruprasad Kalthur, Srinivas Mutalik
Email(s):
ss.mutalik@manipal.edu
DOI:
10.5958/0974-360X.2020.00762.3 
Address:
Sushil Yadaorao Raut1, Manjunath B Joshi2, Guruprasad Kalthur3, Srinivas Mutalik1*
1Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE), Manipal 576104, Karnataka State, India.
2Department of Ageing Research, School of Life Sciences, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India.
3Department of Clinical Embryology, Kasturba Medical College, Manipal Academy of Higher Education, Manipal 576104, Karnataka State, India.
*Corresponding Author
Published In:
Volume - 13,
Issue - 9,
Year - 2020
ABSTRACT:
Objective: Follicle stimulating hormone (FSH) is used widely for the treatment of female infertility. The present study reports various analytical tools to assess the physicochemical properties of FSH in order to investigate the structural integrity, purity and consistency of FSH. Methods: FSH was characterized for appearance, UV absorption, circular dichroism (CD), molecular weight, FTIR as well as standard ELISA test. Results: Visually it is lyophilized, white colored amorphous powder. Histidine, aromatic amino acids,cysteine and methionine showed UV band at around 230nm. The UV absorption maxima value of FSH at the concentration of 5µg/mL in phosphate buffer saline pH 7.4 was found to be 212.4nm. The CD data revealed that pure FSH showed positive antiparallel ß-pleated sheets at 195nm and negative antiparallel ß-pleated sheets at 212nm, which is a well-defined conformation of the FSH secondary structures. SDS-PAGE showed bands with apparent molecular weight of ˜ 30kD. The FTIR analysis showed the characteristic peaks corresponding to carbonyl group (-C=O) of amide, peaks of secondary amide group (-CONH-) and amine (-NH-) group. Standard ELISA test clearly indicated the integrity of protein structure of FSH. The regression coefficient (R2) obtained for the linear equation was found to be 0.9998. Conclusion: The present study revealed successful characterization of FSH.
Cite this article:
Sushil Yadaorao Raut, Manjunath B Joshi, Guruprasad Kalthur, Srinivas Mutalik. Characterization of purified urinary human Follicle Stimulating Hormone. Research J. Pharm. and Tech 2020; 13(9):4315-4319. doi: 10.5958/0974-360X.2020.00762.3
Cite(Electronic):
Sushil Yadaorao Raut, Manjunath B Joshi, Guruprasad Kalthur, Srinivas Mutalik. Characterization of purified urinary human Follicle Stimulating Hormone. Research J. Pharm. and Tech 2020; 13(9):4315-4319. doi: 10.5958/0974-360X.2020.00762.3 Available on: https://rjptonline.org/AbstractView.aspx?PID=2020-13-9-50
REFERENCES:
1. Boivin J, Bunting L, Collins JA, Nygren KG. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod. 2007; 22(6): 1506-12.
2. Vander BM, Wyns C. Fertility and infertility: Definition and epidemiology. ClinBiochem. 2018; 62: 2-10.
3. Bala J, Agrawal Y, Seth S, Goyal V, Kumar P. Correlation between anti-mullerian and follicle-stimulating hormone in female infertility. Int J Health Allied Sci. 2014; 3: 232-36.
4. Petragalia F, Serour GI, ChapronC.The changing prevalence of infertility. Int J Gynecol Obstet. 2013; 123: S4-S8.
5. Direkvand-Moghadam A, Sayehmiri K, Delpisheh A. The global trend of infertility: an original review and meta-analysis. Int J Epidemiol Res. 2014; 1 (1): 35-43.
6. Che S, Eaton A, Moultry AM. A pharmacotherapeutic review of treatment options for infertility in women. Formulary. 2005; 40: 329-41.
7. Lieu CL and Yoshida T. Infertility. In: Dipiro J.T., Talbert R.L., Hayes, P.E., et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 2002; 5th ed. New York: McGraw Hill. Pp.1431–1443.
8. Polyzos NP, Tzioras S, Badawy AM. Aromatase inhibitors for female infertility: a systematic review of the literature. Reprod Biomed Online. 2009; 19(4): 456-71.
9. Smith C, Grimm M, Schwegel M. Treatment of infertility in women. J Am Pharm Assoc. 2012; 52: e27–e42.
10. Weiss JM, Ludwig M, Ortmann O, Diedrich K. GnRH antagonists in the treatment of infertility. Ann Med. 2003; 35: 512-22.
11. Hayden C. GnRH analogues: applications in assisted reproductive techniques. Eur J Endocrinol. 2008; 159: S17–S25.
12. Bassett R, Ceccarelli D, Crisci C, di Tria AM, Mancinelli M, Martelli F, Mendola D, Pezzotti A. Comparative analytical characterization of two commercial human follicle-stimulating hormones extracted from human urine. Curr Med Res ResOpin. 2005; 21(6): 899-905.
13. Palagiano A, Nesti E, Pace L. FSH: urinary and recombinant. Eur J ObstetGynecolReprod Biol. 2004; 115: S30-3.
14. Ulloa-Aguirre A, Damián-Matsumura P, Jiménez M, Zambrano E, Díaz-Sánchez V. Biological characterization of the isoforms of urinary human follicle-stimulating hormone contained in a purified commercial preparation. Hum Reprod. 1992; 7(10): 1371-8.
15. Schmidt A, MacColl R, Lindau-Shepard B, Buckler DR, Dias JA. Hormone-induced conformational change of the purified soluble hormone binding domain of follitropin receptor complexed with single chain follitropin. J Biol Chem. 2001; 276(26): 23373-81.
16. Sjögren HU, Bagger HL. Stabilization of FSH. European patentEP 2598160B1, 2011.
17. Groen BH, Bloemendal M, Mulders JWM, Hadden JM, Chapman D, Van Stokkum IHM, et al. Spectroscopic characterization of recombinant follicle stimulating hormone. SpectrochimActa Part A MolBiomolSpectrosc. 1996; 52(10): 1331–46.
18. Greenfield NJ. Using circular dichroism spectra to estimate protein secondary structure. Nat Protoc. 2006; 1(6): 2876-90.